PROLOR Won New US Patent Covering CTP Platform for Long-Acting Therapeutic Proteins

PROLOR Biotech, Inc. (NYSE: PBTH) today announced that it received a notice of allowance from theU.S. Patent and Trademark Office for a patent application covering thecompany's CTP platform, which has the potential to extend the duration ofactivity of therapeutic proteins.  The allowed claims cover manufacturingmethods for CTP-modified compositions of a wide array of classes oftherapeutic proteins, including hormones, high affinity protein ligands,proteins that induce or regulate an immune response, proteins involved withautocrine and paracrine activities, and mimetics of these therapeuticproteins, as well as other types of proteins.This new U.S. patent is expected to be issued in the next few months.